`Perioperative NSAIDs May Reduce Early Relapses In Breast Cancer: Perhaps Transient Systemic Inflammation After Surgery Leads To These Relapses | 13316
Clinical Pharmacology & Biopharmaceutics
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
In developed countries, metastatic relapse after diagnosis of early stage breast cancer is the common pathway leading to mortality
from the disease. How to prevent relapses remains perhaps the most important unsolved problem in oncology.
As my colleagues and I recently reported, analysis of clinical breast cancer relapse data after mastectomy suggests most distant
relapses occur within 4 years of surgery and are precipitated or accelerated by something that happens around the time of surgery.
Sudden growth from single cells and angiogenesis of avascular micrometastases are indicated. Late relapses are not accelerated by
surgery. Many clinical characteristics of breast cancer can be explained with this hypothesis.
Recent retrospective analysis of clinical data from one Brussels hospital indicates early relapse events were reduced 5-fold
when an NSAID was used as perioperative analgesic. Combining the surgery induced metastatic activity hypothesis with these
Brussels data suggests transient systemic inflammation following primary tumor removal (identified by markers in serum) may
facilitate most metastatic activity and was effectively blocked by the NSAID. While breast cancer is a disease that runs its course in
over a decade, most of the damage seems to occur in the week or two after surgery. This suggests new mechanisms for metastatic
initiation and possibly an effective nontoxic, low cost intervention that may significantly reduce mortality from breast cancer.
Michael Retsky (Ph.D. in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of
Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof
Adj at UANL, Monterrey, Mexico. He was on Judah Folkman?s staff at Harvard Medical School for 12 years. He is on the board of directors of the
Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals